A late Christmas present for Allogene
US clinical hold over Allogene’s entire pipeline has just been lifted.
JP Morgan 2022 – Beam and Mammoth hook big pharma partners
Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.
Ash 2021 – Sangamo and Sanofi enter the sickle cell gene editing fray
SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.
Centessa claims a place in the antitrypsin deficiency pipeline
But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.
Novo bets against Crispr for amyloidosis
Novo moves into amyloidosis not long after Intellia made a splash here.
Intellia proves its point
The first clinical evidence for in vivo gene editing, and a surge in valuation, is to be celebrated. But there is much more to do.
